Jazz Pharmaceuticals
Palo Alto · Founded 2003
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.
Company Facts
- Founded: 2003
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $1M – $10M
- Total funding: $2.8B
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2024)
- Ticker: nasdaq:JAZZ
- Website: jazzpharma.com
- Phone: 6504962651
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/jazz-pharmaceuticals-56266 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.